BOEHRINGER-INGELHEIM
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The prospect of losing one’s sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.”
Utilizing antibody fragment-based technology, which retains the specificity of an antibody while significantly reducing the size of the molecule, may have significant advantages over traditional large molecule approaches for the treatment of retinal diseases, such as GA. When applied to the eye via intravitreal injection, high affinity antibody fragment therapies have the potential to reach the retinal pigment epithelial cells where degeneration is known to occur. This precise technology may help decrease the cellular stresses caused by AMD and prevent further loss of sight.
“Boehringer Ingelheim is one of the leading research and development companies in the field of biologics,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “This is an exciting partnership that brings together Boehringer Ingelheim’s development expertise and CDR-Life’s innovative antibody fragments to provide hope for people living with a blinding retinal disease. We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.”
Boehringer Ingelheim takes a holistic approach to the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. By leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, the company has built a comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
CDR-Life´s preclinical program utilizing antibody fragment-based technology complements this growing portfolio, providing an innovative approach to treat GA.
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization. CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/geographicatrophycollabortationwithcdr-life
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doha Debates Reflects on a Landmark Year of Global Dialogue and Youth Engagement19.1.2026 17:02:00 CET | Press release
In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth In 2025, Qatar Foundation’s Doha Debates strengthened its role as a global platform for truth-seeking dialogue, bringing students and leading thinkers together to explore ideas shaping today’s most urgent questions––from freedom and justice to identity and belonging. Its reach continued to grow, surpassing 13.8 million video views and engaging nearly seven million followers across social platforms, including more than one million YouTube subscribers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119796451/en/ In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth. (Photo: AETOSWire) A major milestone came with season four of The Negotiators, which earned international recognition, winning the Folio A
Evernote Releases v11, Marking a New Chapter in AI-Powered Productivity19.1.2026 17:00:00 CET | Press release
Evernote today announced the release of v11, its first major product update in five years. The new version includes three powerful AI features—AI Assistant, Semantic Search, and AI Meeting Notes—creating smarter ways to capture, retrieve, and manage information in Evernote. With the release of v11, these features are now available to all Evernote customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119103272/en/ Two years of work culminating in a major update V11 is a recognition of Evernote’s evolution under Bending Spoons’ stewardship. Since 2024, Evernote has released more than 250 new features and improvements while also greatly enhancing sync, speed, and reliability. With v11, Evernote ushers in an exciting new phase of development and innovation, bringing customers novel ways to engage with their preferred productivity tool. “Evernote has been part of people’s lives for years, often decades. They’ve always insp
Esmark Expands Global Sports Commitment With Sponsorship of Slovakian Professional Hockey Team19.1.2026 14:00:00 CET | Press release
Sponsorship unites local talent and gives the people of Košice a team of their own Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., announced today it is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. This partnership underscores Esmark’s commitment to supporting sports development and strengthening community connections through the unifying power of athletics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119104207/en/ Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. The Hockey Club Esmark Košice team began competing in the 2HL division of professional ice hockey in Slovakia in the 2025-2026 season. The roster features players from Košice who have been competing for clubs across Slovakia. “The cr
WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP19.1.2026 13:38:00 CET | Press release
A First in Formula 1: WHOOP to Deliver Health Insights Across the Scuderia Ferrari HP Team WHOOP, the human performance company, today announced a new, global partnership with Scuderia Ferrari HP as the Official Health and Fitness Wearable Partner and Team Partner. Starting in the 2026 season, Scuderia Ferrari HP cars and drivers will host the WHOOP logo, while WHOOP will be provided to members of the team to unlock insights on their health, recovery, and fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119602892/en/ This partnership also unlocks a first-of-its-kind integration in which the medical team supporting Scuderia Ferrari HP will work closely with the WHOOP Performance Science team, led by Dr. Kristen Holmes, on enhancing the physical efficiency and recovery for the entire Scuderia Ferrari HP organization. Together, they will work on the foundational elements of health and fitness with a unique human optim
Logistics Reply Announces the Launch of Its Warehouse AI Agent Builder, GaliLEA Dynamic Intelligence19.1.2026 12:32:00 CET | Press release
Logistics Reply, the Reply group company specialising in innovative solutions for supply chain execution and warehouse management, announced today the release of GaliLEA Dynamic Intelligence, the new AI Agent Builder, part of its agentic AI solution natively embedded within the LEA ReplyTM Platform, the microservices-based platform for warehouse and supply chain execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119708355/en/ LEA Reply enables end-to-end supply chain execution while continuously evolving to address increasing levels of automation and operational complexity. Designed to support warehouse operations through a flexible and scalable architecture, LEA Reply enables end-to-end supply chain execution while continuously evolving to address increasing levels of automation and operational complexity. With the introduction of GaliLEA Dynamic Intelligence, the platform enables users to design, configure, and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom